Purdue Frederick’s MS Contin
Executive Summary
Supplemental NDA, filed in July 1987, approved Nov. 8 for MS Contin (morphine sulfate) 200 mg controlled-release tablets. The product, which is indicated for relief of moderate to severe pain, is already available in 15, 30, 60 and 100 mg tablets.